Table 3

Patients’ characteristics of the ART long-term cohort at cohort enrolment stratified by previous enrolment in the Infectious Diseases Institute research cohort

Patients characteristicsResearch cohort, n=345 (34.5%)Clinic patients, n=655 (65.5%)Overall, n=1000p Value
Sex, female, n (%)242 (70.1)377 (57.6)619 (61.9%)<0.001
Age in years, median (IQR)45 (40–50)46 (41–51)45 (40–51)0.217
WHO stages 3 and 4320 (93.3)549 (84.2)869 (87.3)<0.001
BMI (kg/m2), median (IQR)22.4 (19.8–25.0)22.4 (19.8–25.620.3 (18.7–22.7)0.354
Hb (g/dL), median (IQR)13.4 (12.5–14.4)14.5 (13.2–15.9)14.1 (12.8–15.5)<0.001
CD4 count (cells/µL), median (IQR)624 (447–773)450 (329–612)507(363-680)<0.001
HIV RNA <400 (copies/mL), n (%)336 (97.4)622 (95.6)38 (3.8)0.148
Median time on ART (months) (IQR)126 (124–129)124 (121–127)125 (122–128)<0.001
History of
 Tuberculosis48 (13.9)104 (15.9)52 (15.2)0.411
 Cryptococcal meningitis36 (10.4)23 (3.5)59 (5.9)<0.001
 Kaposi’s sarcoma5 (1.5)26 (4.0)31 (3.1)0.030
 Toxoencephalitis8 (2.3)5 (0.80)13 (1.3)0.040
 PJP 5 (1.5)7 (1.1)12 (1.2)0.600
ART type0.934
 First line282 (81.7)534 (81.5)816 (81.6)
 Second line63 (18.3)121 (18.5)184 (18.4)
Number of drug substitutions
 074 (21.5)84 (12.8)158 (15.8)<0.001
 1–2126 (36.5)391 (59.7)517 (51.7)
 3–496 (27.8)134 (20.5)230 (23.0)
 >449 (14.2)46 (7.0)95 (9.5)
History of
 Hypertension83 (24.1)178 (27.2)209 (20.9)0.286
 Cardiovascular diseases15 (4.4)34 (5.2)10 (1.0)0.557
 Diabetes11 (3.2)22 (3.4)32 (3.2)0.886
Tobacco use65 (19.2)164 (25.6)229 (23.4)0.024
Alcohol consumption254 (74.9)482 (75.3)736 (75.2)0.894
  • ART, antiretroviral treatment; BMI, body mass index; Hb, haemoglobin; PJP, Pneumocystis jiroveci pneumonia.